Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

25.06 -0.94 (-3.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 432,244
Open 25.81
Bid (Size) 25.26 (1)
Ask (Size) 26.00 (1)
Prev. Close 26.00
Today's Range 24.34 - 26.71
52wk Range 6.510 - 33.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19

Performance

YTD
+38.68%
+38.68%
1 Month
+23.51%
+23.51%
3 Month
+200.84%
+200.84%
6 Month
+24.24%
+24.24%
1 Year
+38.68%
+38.68%

More News

Read More
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again
Via Investor's Business Daily
7 Biotech Stocks to Buy for Q3
Via InvestorPlace
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Here's How Citi Views Amylyx Pharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
Via Benzinga
Why Is Novavax (NVAX) Stock Rallying Today?
Via InvestorPlace
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug
Via InvestorPlace
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
Via Benzinga
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Via FinancialNewsMedia
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
Via Benzinga
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
Via Benzinga
82 Biggest Movers From Yesterday
Via Benzinga
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
Via InvestorPlace
83 Biggest Movers From Yesterday
Via Benzinga
69 Biggest Movers From Friday
Via Benzinga
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.